



Fresenius Kabi Oncology Limited

Echelon Institutional Area, Plot No. 11,
Sector 32, Gurgaon - 122001,
Haryana, India
T +91-124-4885000, +91-124-3325000
F +91-124-4885003
www.fresenius-kabi-oncology.com

May 30, 2012

The Secretary
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai 4000
Fax Nos: +91 22 2659 823 38

The Secretary
Bombay Stock Exchange Limited
P.J. Towers, Dalal Street
Mumbai 400001
Fax Nos: +91 22 2272 312 3719/2037/2041

Sub: Information under Clause 36 of the Listing Agreement
BSE Scrip Code:- 532545, NSE Symbol- FKONCO, ISIN- INE575G01010

Dear Sir,

This is to inform you that Fresenius Kabi Oncology Limited ("Company") has received a letter dated May 30, 2012 from its promoter shareholder, Fresenius Kabi (Singapore) Pte Ltd. ("FKSL") notifying the Company of its intention to undertake one or more 'offer(s) for sale' on the stock exchanges ("OFS") for sale of up to 23,734,14 equity shares representing approximately 15% of the total share capital of the Company in one or more tranches, subject to receipt of relevant regulatory approvals and the market conditions. The objective of the proposed OFS is to increase the public shareholding of the Company.

Under the Securities Contracts (Regulation) Rules, 1957, the Company is required to increase its public shareholding to at least 25% by June 3, 2013. The current public shareholding of the Company is 10%.


In this regard, FKSL also proposes to make an application to the Foreign Investment Promotion Board ("FIPB") for seeking the approval of the FIPB in relation to the proposed OFS given that investors such as FIIs, QFIs, FVCIs and NRIs may participate in the OFS and any purchase by such investors will be subject to the prior approval of the FIPB as per the extant foreign exchange regulations.

The implementation of one or more OFS by FKSL will be subject to the receipt of approval from the FIPB and the market conditions.

You may kindly take note of the above.

Thanking you,

For Fresenius Kabi Oncology Limited


Nikhil K. Shreshthia
Company Secretary

